April 20 (Reuters) - Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic drugs and boosted federal research funding.
Shares of Atai Life Sciences jumped 21% before the bell, while Definium Therapeutics rose 15% and Compass Pathways climbed 26%. GH Research gained 19%, Enveric BioSciences added 7%, and U.S.‑listed shares of Cybin were up about 15%.
